Testing a new MS drug similar to Ocrevus
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study compares a new drug called PB018 with the approved MS drug Ocrevus. Researchers want to see if PB018 works similarly and is safe for people with relapsing or progressive forms of MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with relapsing-remitting MS (RMS) or primary progressive MS (PPMS) using McDonald criteria
- Shown signs of recent MS disease activity (as defined by the study)
- Stable neurological condition for at least 30 days before screening and first treatment
- Disability score (EDSS) between 0–6.0 for RMS patients, or 3.0–6.5 for PPMS patients
- Able to undergo MRI scans and not allergic to corticosteroids like methylprednisolone
- Not on certain prohibited medications or treatments during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
This trial tests a new way of taking Ocrelizumab as a shot under the skin, for people with MS who are already on a similar treatment and want to switch. The goal is to see if switching is safe and works well.
This study tests an experimental drug called RO7121932 in people with multiple sclerosis. The goal is to see how safe it is and how the body processes it. It might help by offering a new way to manage the condition.
This study compares how well two medicines, Kesimpta and Ocrevus, work for people with multiple sclerosis when used in real life. It looks at patient records to see which treatment might be more effective.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.